ERBB2 and breast cancer: We report the results of a comparative clinical trial conducted to compare pharmacokinetics, efficacy, safety and immunogenicity of PF-05280014 versus trastuzumab-EU, each administered in combination with docetaxel and carboplatin, as neoadjuvant treatment for patients with operable HER2+ breast cancer.22 It was hypothesised that PF-05280014 was non-inferior to trastuzumab-EU, based on pharmacokinetics data.